1,500
Participants
Start Date
July 9, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
August 31, 2026
Finerenone
Oral finerenone.
Empagliflozin
Oral empagliflozin.
RECRUITING
CON-10022 Atlanta, GA Investigational Site, Atlanta
RECRUITING
CON-10004 Fairhope, AL Investigational Site, Fairhope
RECRUITING
CON-10002 Kansas City, MO Investigative Site, Kansas City
RECRUITING
CON-10030 Baton Rouge, LA Investigational Site, Baton Rouge
RECRUITING
CON-10015 Austin, TX Investigational Site, Austin
RECRUITING
CON-10045 Amarillo, TX Investigational Site, Amarillo
RECRUITING
CON-10075 El Centro, CA Investigational Site, El Centro
RECRUITING
CON-10024 Sacramento, CA Investigational Site, Sacramento
RECRUITING
CON-21004 Braganca Paulista, Sao Paulo Investigational Site, Bragança Paulista
RECRUITING
CON-21003 Goiania, Goias Investigational Site, Goiânia
RECRUITING
CON-21007 Joinville, Santa Catarina Investigational Site, Joinville
RECRUITING
CON-21049 Sao Paulo, Sao Paulo Investigational Site, São Paulo
RECRUITING
CON-11012 Surry, BC Investigational Site, Surrey
RECRUITING
CON-11007 North York, ON Investigational Site, North York
RECRUITING
CON-11005 Sherbrooke, QC Investigational Site, Sherbrooke
Saint Luke's Mid America Heart Institute
UNKNOWN
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
INDUSTRY
Colorado Prevention Center
OTHER